Discovering a new drug is only the beginning: progress and challenges in expanding access to BDQ for MDR-TB treatment-Reference-Cited by-同舟云学术

Discovering a new drug is only the beginning: progress and challenges in expanding access to BDQ for MDR-TB treatment

Published:2020-10-01 Issue:10 Volume:24 Page:985-986
ISSN:1027-3719
Container-title:The International Journal of Tuberculosis and Lung Disease
language:en
Short-container-title:int j tuberc lung dis

Author:

Cox H.¹,Shah N. S.²,Castro K. G.³

Affiliation:

1. Institute of Infectious Disease and Molecular Medicine and Wellcome Centre for Infectious Disease Research, University of Cape Town, Cape Town, South Africa

2. Rollins School of Public Health and School of Medicine, Emory University, Atlanta, GA

3. Rollins School of Public Health and School of Medicine, Emory University, Atlanta, GA, Bureau for Global Health, US Agency for International Development, Washington, DC, USA, , Email: helen.cox@uct.ac.za

Publisher

International Union Against Tuberculosis and Lung Disease

Subject

Infectious Diseases,Pulmonary and Respiratory Medicine

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The IJTLD – the story continues;The International Journal of Tuberculosis and Lung Disease;2022-08-01

2. Evaluation of a novel inhibitor of aspartate semialdehyde dehydrogenase as a potent antitubercular agent against Mycobacterium tuberculosis;The Journal of Antibiotics;2022-04-14

3. A bold new future for the IJTLD;The International Journal of Tuberculosis and Lung Disease;2021-10-01

4. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort;Pulmonology;2021-09